Back to top

Acadia Pharmaceuticals price target raised to $30 from $29 at BofA

BofA analyst Tazeen Ahmad raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $30 from $29 and keeps a Buy rating on the shares afte...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

ACADIA Pharmaceuticals Inc. (ACAD)